Cybin News

Cybin Inc. CEO to Speak at Milken Global Conference

TipRanksApr 25 08:08 ET

Cybin to Participate at the 27th Annual Milken Institute Global Conference

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled "Collaborating for Improved Mental Health."

BusinesswireApr 25 07:30 ET

Cybin Inc. Unveils Promising Psychedelic Research

TipRanksApr 18 08:17 ET

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

- Publication explores structure-activity relationships ("SAR") of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist

BusinesswireApr 18 07:30 ET

Cedar Clinical Research Selected as Clinical Research Site for Cybin's Phase 3 Study of CYB003

VANCOUVER, BC, April 17, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behaviora

PR NewswireApr 17 07:00 ET

Cybin Inc. Secures Patent, Progresses MDD Therapy

TipRanksApr 16 08:09 ET

Express News | Cybin Announces Grant Of Additional US Patent In Support Of Its CYB003 Breakthrough Therapy Program For Major Depressive Disorder

Moomoo 24/7Apr 16 07:35 ET

Express News | Cybin Inc - to Commence Enrollment for a Multinational, Multisite Phase 3 Program Evaluating Cyb003 in Major Depressive Disorder Around Mid-Year 2024

Moomoo 24/7Apr 16 07:30 ET

Express News | Cybin Inc - Newly Issued Patent Expected to Provide Exclusivity Until at Least 2041

Moomoo 24/7Apr 16 07:30 ET

Express News | Cybin Announces Grant of Additional U.S. Patent in Support of Its Cyb003 Breakthrough Therapy Program for Major Depressive Disorder

Moomoo 24/7Apr 16 07:30 ET

Cybin Announces Grant of Additional U.S. Patent in Support of Its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 11,958,807 in support of its CYB003 program in Major Depressive Disorder ("MDD").

BusinesswireApr 16 07:30 ET

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic

BusinesswireApr 10 07:30 ET

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024.See previous edition Psychedelics Headlines: Substitution Survey, Fr

BenzingaMar 30 08:57 ET

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More

FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c

BenzingaMar 20 14:49 ET

Cybin Inc. Secures $150M for Psychedelic Research

TipRanksMar 19 12:07 ET

Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million

Yahoo FinanceMar 19 11:53 ET

Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up

Yahoo FinanceMar 18 11:23 ET

Cybin, Inc. Shines at Dallas Investor Event

TipRanksMar 18 08:18 ET

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation

BusinesswireMar 18 07:30 ET

Sector Update: Health Care Stocks Softer Friday Afternoon

Health care stocks fell Friday afternoon with the NYSE Health Care Index falling 0.8% and the Health Care Select Sector SPDR Fund (XLV down 0.5%. The iShares Biotechnology ETF (IBB) rose 0.1%. In corp

MT NewswiresMar 15 13:52 ET